Stemline Therapeutics announced earlier today that it has exclusively licensed worldwide rights to develop and commercialize a selective small molecule rearranged during transfection kinase inhibitor from the CRT Pioneer Fund LP, a U.K. based fund manager. The RET inhibitor was designed by scientists at Cancer Research UK Manchester Institute at the University of Manchester . The preclinical compound has been designated SL-1001 and is expected to enter the clinic in 2020. “RET kinase genetic alterations have been found in a diverse range of cancers and, we believe, is a clinically validated target in multiple indications,” Stemline said in a statement. “SL-1001 is an oral RET kinase inhibitor that has demonstrated potent, selective, preclinical anti-cancer activity, both in vitro and in vivo, in RET-driven tumor models,” it added. “SL-1001 is an ideal strategic fit for us, given its targeted mechanism of action and potential for streamlined development,” commented Stemline’s CEO, Ivan Bergstein. He continued, “Building upon our team’s proven track record of success, culminating with the recent ELZONRIS approval, we intend to advance SL-1001 swiftly through the clinical and regulatory process with an eye towards achieving our goal of helping more patients succeed in their fight against cancer.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.